IVA Inventiva S.A. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$4.77

Period return

+0.59 (+14.11%)

Volume

352.2K

2026-06-01O $4.91 H $4.96 L $4.67 C $4.77MA5 $5.06MA20 $5.28MA60 $5.53MA120 $5.59

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 03. 19.MediumBUY2 months ago
Truist Securities: Buy
US analyst rating / recommendation change.
2026. 01. 28.MediumBUY4 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 01. 12.MediumBUY5 months ago
Leerink Partners: Outperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $15.13 · 13 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Sector: Healthcare
Industry: Biotechnology
HQ: Daix, France
Fiscal year end: —
Employees: 69
IPO date: —

View details →